The advantage for apixaban in preventing VTE recurrence was consistent across subgroup analyses that accounted for age, sex, active cancer, chronic kidney disease, history of bleeding, and three ...

CHICAGO — For patients with cancer requiring extended anticoagulant therapy, a strategy of reduced-dose apixaban was noninferior to full-dose apixaban for prevention of cancer-associated ...

For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...

The findings of this post hoc analysis suggest that both apixaban and aspirin may be effective in preventing adverse clinical outcomes in patients with a history of cancer and cryptogenic stroke.

Bayer’s investigational factor XIa inhibitor asundexian was inferior to BMS’ and Pfizer’s blockbuster blood thinner Eliquis (apixaban) in the Phase III OCEANIC-AF study.

Eliquis is used to treat and prevent blood clots in certain situations. Find out what the recommended dosages are, how to take the drug, and more.

Background: There are no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial fibrillation (AF) ...

The initial Food and Drug Administration labeling of apixaban for patients with ESKD was based on data from a single 5-mg dose of apixaban in 8 patients with ESKD receiving hemodialysis, 11 consistent ...

The use of apixaban (Eliquis; Bristol-Myers Squibb) over rivaroxaban (Xarelto; Bayer/Janssen) in patients with atrial fibrillation (AF) and valvular heart disease is associated with better clinical ...

In patients with a-fib and valvular heart disease, treatment with apixaban was associated with a lower risk of stroke or systemic embolism and bleeding vs rivaroxaban.

WASHINGTON — In patients with atrial fibrillation requiring stroke prevention, the novel factor XIa inhibitor asundexian was associated with lower bleeding rates compared with apixaban ...